The D 3 dopamine (DA) receptor is a member of the D 2 -like DA receptor family. While the D 2 receptor is abundant especially in motor-regions of the striatum, the D 3 receptor shows a relative abundance in limbic regions and globus pallidus. This receptor is of current interest in neurology because of its potential involvement in psychiatric and motor complications in Parkinson's disease and the possibility that dopamine D 3 -preferring agonist therapy might delay progression of the disorder. Abbreviations: DA = dopamine; DC = dorsal caudate; DP = dorsal putamen; GP = globus pallidus; PET = positron emission tomography; ROI = region of interest; VS = ventral striatum
The D 3 dopamine (DA) receptor is a member of the D 2 -like DA receptor family. While the D 2 receptor is abundant especially in motor-regions of the striatum, the D 3 receptor shows a relative abundance in limbic regions and globus pallidus. This receptor is of current interest in neurology because of its potential involvement in psychiatric and motor complications in Parkinson's disease and the possibility that dopamine D 3 -preferring agonist therapy might delay progression of the disorder. Preclinical data indicate that striatal levels of the D 3 (but not the D 2 ) DA receptor are decreased following lesion of nigrostriatal DA neurons; at present, there are no in vivo data on this receptor subtype in Parkinson's disease. The objective of this positron emission tomography study was to compare (25%, P < 0.01) binding were similarly increased, especially on the side contra-lateral to the symptoms. In the midbrain, presumably containing D 3 receptors localized to the substantia nigra, [ 11 C]-(+)-PHNO binding was normal. Decreased
Introduction
As dopamine (DA) has an established (idiopathic Parkinson's disease) or suspected (schizophrenia, addiction) involvement in a variety of human brain disorders (Ehringer and Hornykiewicz, 1960; Snyder et al., 1974; Di Chiara and Imperato, 1988) , there has been much interest in understanding the role of the different DA receptor subtypes (D 1 -like, including D 1 and D 5 ; and D 2 -like, including D 2 , D 3 and D 4 ) in these conditions. To date, D 1 and especially D 2 DA receptors have been the focus of most clinical interest. However, because of its preferential localization to the human limbic system (Landwehrmeyer et al., 1993; Murray et al., 1994) , involved in motivation reward and emotion (for review see Ikemoto and Panksepp, 1999) , the DA D 3 receptor (Sokoloff et al., 1990) has been considered a potentially important drug target (Meltzer, 1991; Joyce, 2001 ) and possible pathophysiological factor (Joyce and Millan, 2007) in human conditions involving a brain DA abnormality. The emerging D 3 receptor literature in Parkinson's disease, based on experimental animal findings and human drug studies, implicates this receptor in the pathophysiology and treatment of the disorder. Loss of dopaminergic input to this receptor could provide the basis for some psychiatric problems associated with Parkinson's disease [e.g. depression or anhedonia; (Lemke et al., 2005) ], whereas other disturbances [e.g. pathological gambling; (Dodd et al., 2005; Lader, 2008) ] consequent to DA agonist therapy, might be explained by excessive D 3 receptor-linked activity Guillin et al., 2003; Richtand, 2006) . Although this DA receptor subtype is not predominant in motor regions of the human striatum [e.g. putamen; (Murray et al., 1994) ], some animal data suggest that the D 3 receptor might be involved in normal motor function (Accili et al., 1996; Ekman et al., 1998; Gendreau et al., 1997; Xu et al., 1997; McNamara et al., 2006; Pritchard et al., 2007) and in development of abnormal motor responses caused by prolonged treatment with DA substitution therapy in Parkinson's disease. In this regard, increased D 3 receptor levels, as inferred from [ 3 H]7-OH-DPAT binding in MPTP-intoxicated monkeys have been associated with emergence of behavioural sensitization (levodopa-induced dyskinesias) which was attenuated by administration of a selective D 3 partial-agonist (BP 897) Guigoni et al., 2005) . A separate line of investigation provides evidence, albeit controversial, that stimulation of the D 3 receptor might actually protect nigrostriatal DA neurons from toxic damage. This was suggested in part by the ability of D 3 -preferring DA agonists (e.g. pramipexole) to protect against DA neuron damage caused by MPTP and 6-hydroxydopamine (for review see Joyce and Millan, 2007) . Furthermore, in a single-photon emission computed tomography ([   123   I ]b-CIT) imaging study, patients with Parkinson's disease who received pramipexole displayed a less severe loss of striatal DA transporter binding (at 46 months) relative to patients receiving levodopa (Parkinson Study Group, 2002) . However, the incidence of dyskinesias was not significantly different between treatment groups (Constantinescu, 2007) and the issue of the D 3 receptor and neuroprotection in Parkinson's disease is not yet established because of a variety of limitations to study design (for discussion see Clarke and Guttman, 2002 (Rinne et al., 1990; Brooks et al., 1992) , as is the case in animals with induced-parkinsonism (Graham et al., 1990) . This finding is generally considered to represent a form of denervation supersensitivity to compensate for diminished DA transmission (Lee et al., 1978) . In the case of the D 3 receptor, animal studies employing Parkinson's disease models generally show, paradoxically, the reverse, in which sustained interruption of DA transmission is associated with decreased striatal D 3 receptor concentration as inferred from [
3 H]7-OH-DPAT binding and D 3 receptor mRNA procedures (Levesque et al., 1995; Morissette et al., 1998) . The biological significance of the D 3 reduction, which appears to be related to decreased D 1 -stimulated brain-derived neurotrophic factor (BDNF) (Guillin et al., 2001) (Wilson et al., 2005) to distinguish between the DA receptor in the high (D high 2 : G-protein coupled state, responsible for the functional effects of DA) and low-affinity states (D low 2 : G-protein uncoupled, functionally inert) (Seeman et al., 1993 (Freedman et al., 1994) . In vivo, a study in the baboon using a D 3 partial agonist (BP897) (Narendran et al., 2006) (Rabiner et al., 2007 (Rabiner et al., , 2008a (Brooks, 2003; Hurley and Jenner, 2006) ]. (First et al., 1994) ]. All subjects completed mood and personality questionnaires. Table 1 summarizes characteristics of the subjects in the study.
Materials and Methods

Subjects
PET imaging activity, 864.8 ± 268 mCi/mmol; mean mass, 4.52 ± 2.2 mg). Raw data were reconstructed by filtered-back projection (Defrise et al., 1997) . Standard spin echo proton-density weight magnetic resonance images (MRI; TE = 17, TR = 6000, field of view = 22 cm 2D, 256 Â 256, slice thickness = 2 mm, NEX = 2) were obtained (Signa 1.5T MRI scanner, General Electric Medical Systems, Milwaukee, WI) for purpose of region of interest (ROI) delineation. ROI delineation and analysis was performed by using in-house image analysis software for automated quantification of PET data (ROMI) (Rusjan et al., 2006) . In brief, a standard brain template (International Consortium for Brain Mapping/Montreal Neurological Institute 152 MRI) containing a set of predefined cortical and subcortical ROIs [based on (Talairach et al., 1988) and (Kabani et al., 1998) 2.6 ± 2.1 6.5 ± 6.7 0.14 IDS 3.0 ± 3.2 7.9 ± 5.9 0.05 BPS 9.1 ± 2.3 10.0 ± 3.2 0.5 Purdue Pegboard task PPT -Dominant hand 14 ± 2 11 ± 2 0.08 PPT -Non-dominant hand 14 ± 1 11 ± 3 0.05 PPT -Both hands 11 ± 1 8 ± 3 0.05 PPT -Symptomatic hand 11 ± 2 0.02 PPT -Asymptomatic hand 12 ± 3 Disease duration 3 ± 2 years Hoehn-Yahr stage 8 H&Y I; 2 H&Y II UPDRS total 15 ± 3 UPDRS III symptomatic-side 5 ± 2 UPDRS III asymptomatic-side 1 ± 1 Symptomatic-side 3 L/7 R Italic for P-value indicate significance at P < 0.05. NART = National Adult Reading Task (Nelson, 1982) ; MMSE = Mini-mental state examination (Folstein et al., 1975) ; BDI = Beck Depression Inventory (Beck et al., 1961) ; IDS = Inventory of Depressive Symptomatology (Rush et al., 2000) ; BPS = Boredom Proneness Scale (Farmer and Sundberg, 1986) ; PPT = Purdue pegboard task (Lafayette-Instrument-Company, 1985) ; H&Y = Hoehn-Yahr stage (Hoehn and Yahr, 2001 ); UPDRS total = Unified Parkinson Disease Rating Scale (Fahn and Elton, 1987) ; UPDRS III = motor examination scale; UPDRS III symptomatic/asymptomatic-side rating = UPDRS III items including, leg agility, rapid alternating hand pronation and supination, open-close hand movement, finger taps, upper and lower limb rigidity, action or postural tremor and tremor at rest. a Significantly different from asymptomatic hand.
refined ROIs were aligned and resliced to match the dimension of the PET images [normalized mutual information algorithm implemented under SPM2; (Studholme et al., 1999) ]. Three bilateral sub-compartments of the striatum [dorsal caudate (DC); dorsal putamen (DP); and VS] and GP were selected as ROIs and the cerebellar cortex (excluding vermis) was selected as the region of reference [details in (Rusjan et al., 2006) ]. We also investigated [ ]-(+)-PHNO time activity curves were obtained from the dynamic data and specific binding (BP ND ) was estimated in each ROI using the simplified reference tissue method (SRTM) (Lammertsma and Hume, 1996) ]raclopride binding were generated by using DEPICT (Gunn et al., 2002) . This method of parameter estimation requires no a priori decision about model structure (data-driven) and employs the basis-pursuit approach. The tissue time activity curve of the cerebellar cortex reference region served as input function. Each parametric map was spatially normalized to an anatomical template (MNI) using SPM2 normalization and co-registration tools. Once in the same space, BP ND maps were statistically investigated to assess significant contrasts between groups in ROIs (explicit mask) using independent sample t-test analysis (SPM5). This approach is aimed at detecting between group changes in neuroreceptor ligand binding at the voxel-level with no a priori anatomical hypothesis and enables to circumvent some of the limitations of ROI placement.
Results
Both radioligands had high uptake and quantifiable signal in the striatum and pallidum. However, [
11 C]-(+)-PHNO and and VS compared with DP and DC (P < 0.01) (Fig. 1A and B) . GP extending into a region that appears to correspond to the former 'substantia inominata' (Heimer, 2003) including the ventral pallidum, olfactory area, caudal ventral striatum and nucleus basalis (MNI coordinates, 20, À10, À4; t max = 5.28, P corrected = 0.04) and increased [ 11 C]-(+)-PHNO (MNI coordinates, À25, À4, À6; t max = 3.98, P corrected = 0.006) and [ 11 C]raclopride BP ND (MNI coordinates, À 28, À8, 2; t max = 4.82, P corrected = 0.08) in the DP (greater on the side contra-lateral to symptoms) of the subjects with Parkinson's disease relative to the controls (Fig. 4) .
Discussion
Our major finding is a reduction in Suzuki et al., 1998; Gurevich and Joyce, 1999) . It is also in line with in vivo (Narendran et al., 2006; Rabiner et al., 2007 Rabiner et al., , 2008a and in vitro (Freedman et al., 1994) data suggesting that [ 11 C]-(+)-PHNO is a D 3 -preferring agonist, whereas raclopride has equal affinity for both D 2 -like DA receptor subtypes (Malmberg et al., 1994) . Indeed, [ (Freedman et al., 1994; van Vliet et al., 2000) as well as a higher affinity for the D 3 receptor relative to DA (Freedman et al., 1994; Seeman et al., 2006) . The higher affinity of this ligand for the D 3 receptor and its potency at displacing endogenous DA from this receptor [unlike raclopride ] can explain its higher binding in D 3 -rich areas compared with that of [ 11 C]raclopride. However, our observation that (Landwehrmeyer et al., 1993; Murray et al., 1994) . One possible explanation is that the very low level of DA in the GP relative to striatum (Ehringer and Hornykiewicz, 1960) Nandhagopal et al., 2008) . We now extend this finding to [ 11 C]-(+)-PHNO; further supporting the notion that this ligand primarily binds to D 2 receptors in the DP. Although the general assumption, based on preclinical findings, is that increased tracer binding reflects increased receptor density (B max ) (for review see Wichmann and DeLong, 2003) , it is possible that very low DA levels in the putamen also contribute to increased BP ND (decreased K d ). Although Parkinson's disease-related increases in BP ND , observed with both ligands, were of equal magnitude and intercorrelated in the DP, [ (Whone et al., 2003) . However, in a non-human primate model (MPTP) of very early Parkinson's disease, clinically asymptomatic animals showed decreased DA levels in GP (Pifl et al., 1992) .
Given the selectivity of [ 11 C]raclopride which binds to both the DA receptor in high-and low-affinity states) (Seeman et al., 1993) , an alternative explanation is that decreased [ is sustained by many in vitro studies, it is unclear whether this state of the receptor can actually be measured in vivo (Sibley et al., 1983; McCormick et al., 2008) .
Although the findings are not entirely consistent, animal data generally demonstrate that D 3 receptor binding in one or more dopaminoceptive field is decreased following treatment with toxins (6-OHDA; MPTP) that damage brain DA neurons (Levesque et al., 1995; Hurley et al., 1996a; Morissette et al., 1998; Wade et al., 2001) . It is less certain from preclinical studies however, whether decreased DA transmission per se is sufficient to cause reduction in receptor concentration: both no change (Levesque et al., 1995) and decreased (Stanwood et al., 2000) D 3 receptor expression have been reported in reserpinized and antipsychotic treated animals. Given that D 3 binding reductions reported in (post-mortem) animal studies are not likely to be confounded by possible competition between DA and D 3 radioligand at the receptor site (as the tissue is washed and binding conducted in some studies at saturation), the simplest explanation for our finding of low g. GABA-dynorphinergic substance P neurons (Surmeier et al., 1996) ]. Data from 6-OHDA lesioned-animals argue against a mere disappearance of autoreceptors on DA axon terminals since parallel changes in D 3 receptor binding and mRNA expression in post-synaptic cells have been shown to occur (Levesque et al., 1995) . This conclusion is also consistent with the limited destruction, in early stage Parkinson's disease, of ventral tegmental innervation to limbic striatum (Javoy-Agid et al., 1981) and with the finding of minimal expression of D 3 receptor mRNA in ventral tegmental DA cells (Gurevich and Joyce, 1999) . Thus, the most probable explanation is that part of the [ (Guillin et al., 2001) ], which is reported to be reduced in Parkinson's disease (Parain et al., 1999) .
Investigations of D 3 mRNA distribution in the human midbrain show D 3 expression ranging from low in SN reticulata (presumably on GABA neurons) to very low in SN compacta, to virtually absent in the ventral tegmental area. However, D 3 receptor mRNA is present in tyrosine-hydroxylase positive neurons, suggesting that D 3 receptors in midbrain are in part localized to DA neurons (Gurevich and Joyce, 1999) . Our failure to find decreased [ (Quik et al., 2000) . In our study, normal midbrain [
11 C]-(+)-PHNO binding [presumably exclusively to D 3 (Rabiner et al., 2008b) . It has been suggested that the unusual GP kinetics could result from the D 3 binding fraction in this brain area. However, despite our finding of different D 3 receptor fraction in Parkinson's disease and control subjects, we found that GP BP ND was estimated with equal precision across groups (covariance of the fit controls: 9%; Parkinson's disease: 12.5%) and that the coefficients of variation were similar (controls: 12.3%; Parkinson's disease: 9.1%). Another factor which could potentially influence BP ND measurement is brain morphological differences between groups. However, the possibility of brain atrophy in Parkinson's disease explaining decreased [
11 C]-(+)-PHNO BP ND is minimized because of the absence of grey-matter density differences in ROIs across groups (data not shown). Furthermore, adjustment for the effect of partial-volume (which minimizes the impact of morphological differences on outcome measure) resulted in a similar reductions in BP ND in Parkinson's disease (GP: À30%; VS: À8%).
What is the functional significance of decreased explained by some loss of the DA D 3 receptor, the significance of our findings depends upon the biological role of the D 3 receptor in human brain, which has yet to be established. In general, animal data suggest that the D 3 receptor might exert an inhibitory effect on motor function. This is supported by some animal findings of increased locomotor activity in transgenic mice lacking the D 3 receptor (Accili et al., 1996; Xu et al., 1997; McNamara et al., 2006) and, in normal mice exposed to D 3 antisense treatment (Ekman et al., 1998) or to low doses of D 3 -preferring DA antagonists (Gendreau et al., 1997; Pritchard et al., 2007) . Similarly, in the DA neuron-lesioned non-human primate, D 3 antagonist exposure enhances the anti-parkinsonian effects of levodopa (Silverdale et al., 2004) . Taken together, these findings suggest that downregulation of the D 3 receptor might represent an adaptation to compensate for the loss of motor function associated with DA neuron damage in Parkinson's disease. However, seemingly at odds with the animal data, we found a positive correlation between decreased performance on the Purdue Pegboard motor task and D 3 binding suggesting that D 3 receptor stimulation could be involved in normal control over motor function. The literature is also unclear as to the role of DA in the GP. Interestingly, some imaging data suggest that decreased DA activity in the internal segment of the GP (which appeared to be affected in our study; see Results section) is associated with the loss of the 'honeymoon phase' to levodopa therapy and the onset of motor fluctuations (Brooks, 2003) . Given the preferential distribution of the D 3 receptor in limbic brain it could be anticipated that loss of the receptor could impair mood, emotional and motivational functions. In this regard, our finding of a positive relationship between lowered-mood and decreased [ On one hand, it has been suggested that D 3 receptor is implicated in treatment-induced complications in Parkinson's disease, particularly psychiatric side-effects including pathological gambling and other compulsive behaviours. On the other hand, D 3 receptor activation has a speculated (though still unconfirmed in the human) neuroprotective action on DA neurons. Future investigations of the association between brain D 3 receptor levels and treatment-induced psychiatric problems and disease status in Parkinson's disease as well as more fundamental studies of the factors responsible for controlling receptor expression [e.g. the dopamine D 1 receptor; (Guillin et al., 2001) ] are warranted.
